UBS Group
WGS icon

UBS Group’s GeneDx Holdings WGS Stock Holding History

UBS Group’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,000
Closed -$831K – 10991
2025
Q2 		$831K Buy
+9,000
New +$707K ﹤0.01% 5599

Other funds holding WGS

Corvex Management
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

UBS Group's WGS Position: Q2 2026 in Review

UBS Group increased its GeneDx Holdings (WGS) stake by 311% in Q2 2026, buying an estimated $8.97M and bringing the position to 208,663 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

UBS Group first reported a position in WGS in Q1 2021 and has held it in 18 quarters since. The position peaked at $92.5M in Q2 2025. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

  • UBS Group held 208,663 shares of GeneDx Holdings worth $14.3M as of Q2 2026.
  • UBS Group bought 157,838 GeneDx Holdings shares in Q2 2026, an estimated $8.97M.
  • GeneDx Holdings made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3040 holding.
  • UBS Group first reported a position in GeneDx Holdings in Q1 2021 and has held it in 18 quarters since.
  • UBS Group's GeneDx Holdings position peaked at $92.5M in Q2 2025.
  • 223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.